Webinar :Register now for Commodity Ki Paathshala webinar on ‘FPOs & Agriculture Marketing-The Beginning of a New Era’ on January 22, 4pm
you are here: HomeNewsBusiness

Coronavirus treatment: Patanjali to share outcome of clinical trial of its COVID-19 drug, claims 'major breakthrough'

In an earlier interaction Balkrishna told Moneycontrol that the company had launched clinical trials on humans to find a cure for COVID-19 after receiving regulatory approvals.

June 24, 2020 / 09:29 PM IST

Patanjali Ayurvedic Medicines has announced that it will disclose the outcome of its controlled clinical trial of randomised placebo on COVID-19 patients.

The research was jointly conducted by the Patanjali Research Institute, Haridwar and the National Institute of Medical Science, Jaipur.

Co-founder Baba Ramdev and Managing Director Acharya Balkrishna will address the media at 12 noon on June 23 (today), to share “the major breakthrough in cure of COVID-19,” the company said. The team of scientist, researchers and doctors involved in the trials will also be present at the video conference.

Medicines from the research are being manufactured by Divya Pharmacy, Haridwar and Patanjali Ayurved, Haridwar, it added.

In an earlier interaction Balkrishna told Moneycontrol that the company had launched clinical trials on humans to find a cure for COVID-19 after receiving regulatory approvals.

Close

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

"We are not talking about an immunity booster.  We are talking about a cure," he said. The clinical trials have begun in Indore and in Jaipur after Patanjali secured permission in early June.

Also Read:  5-day coronavirus treatment to cost no more than Rs 30,000: Hetero

The decision to diversify into the hunt for a cure for the deadly pandemic is unusual for Patanjali because the rush to develop treatments for COVID-19 has so far been led by Big Pharma.

Large pharmaceutical companies such as Gilead Sciences, Pfizer, Johnson & Johnson, Moderna, Inovio Pharmaceutcials and GlaxoSmithKline, among others, are racing to find a successful vaccine.

Balacharya, as Acharya Balkrishna is popularly referred to, said the group began treating people for COVID-19 as early as in February 2020. "By March, we had already treated several thousand people.  But they were not part of an evidence-based, clinical trial.  To get our discovery registered as a cure, we had to go through clinical trials," he had added.

Click to read all of our coverage on Coronavirus
Moneycontrol News
first published: Jun 23, 2020 10:32 am
Sections